24
https://pubmed.ncbi.nlm.nih.gov/38114573
A novel HER2-targeted therapy, trastuzumab deruxtecan, shows promising antitumor activity against trastuzumab-resistant metastatic gastric cancer.
https://pubmed.ncbi.nlm.nih.gov/38114573
A novel HER2-targeted therapy, trastuzumab deruxtecan, shows promising antitumor activity against trastuzumab-resistant metastatic gastric cancer.